WAT
53
6
SRE
66
3
ADP
66
2
AMZN
55
-3
ABT
62
5
CRM
65
6
PAYX
51
4
FE
52
3
IFF
56
3
ORLY
60
7
URI
60
7
C
60
2
SWK
61
5
PH
73
3
HD
55
8
DD
60
4
BBY
36
-4
SIG
49
6
F
47
4
ISRG
76
2
WAT
53
6
SRE
66
3
ADP
66
2
AMZN
55
-3
ABT
62
5
CRM
65
6
PAYX
51
4
FE
52
3
IFF
56
3
ORLY
60
7
URI
60
7
C
60
2
SWK
61
5
PH
73
3
HD
55
8
DD
60
4
BBY
36
-4
SIG
49
6
F
47
4
ISRG
76
2
Financhill
Back

Sangamo Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
49

SGMO
Sangamo Therapeutics

Last Price:
1.95
Seasonality Move:
29.11%

7 Day Trial

ALL ACCESS PASS

$ 7

Start Investing Smarter Unlock Louis Navellier's Stock Grader for free

Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.

Sangamo Therapeutics Price Quote

$1.95
-0.01 (0%)
(Updated: November 22, 2024 at 5:44 AM ET)

Sangamo Therapeutics Key Stats

Sell
49
Sangamo Therapeutics (SGMO) is a Sell
Day range:
$1.89 - $2.03
52-week range:
$0.30 - $3.18
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
7.27
P/B ratio:
10.45%
Volume:
3.3M
Avg. volume:
11.9M
1-year change:
424.34%
Market cap:
$408.9M
Revenue:
$176.2M
EPS:
$-0.75

How Much Does Sangamo Therapeutics Make?

Is Sangamo Therapeutics Growing As A Company?

  • What Is Sangamo Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 4.26%
  • What Is Sangamo Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Sangamo Therapeutics Stock Price Performance

What Is Sangamo Therapeutics 52-Week High & Low?

Sangamo Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Sangamo Therapeutics?

Is Sangamo Therapeutics Cash Flow Positive?

  • What Is SGMO Cash Flow From Operations?
    Cash flow from operations (TTM) is -$114.3M
  • What Is Sangamo Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $21.6M
  • What Is Sangamo Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $73.9M

Sangamo Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    SGMO return on invested capital is -199.86%
  • What Is Sangamo Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -93.87%
  • What Is SGMO Return On Equity?
    ROE is a measure of profitability and is -199.86%

Sangamo Therapeutics Earnings Date & Stock Price

Sangamo Therapeutics Competitors

  • Who Are Sangamo Therapeutics's Competitors?
    Below is a list of companies who compete with Sangamo Therapeutics or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • Armata Pharmaceuticals Inc (ARMP)
    • Perspective Therapeutics Inc (CATX)
    • Pfizer Inc (PFE)
    • Protalix BioTherapeutics Inc (PLX)

Sangamo Therapeutics Dividend Yield

Sangamo Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 425.77% 97.09%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 4
Sell Recommendations: 0
Price Target: 6.20
Upside from Last Price: 216.33%

Major Shareholders

  • How many SGMO shares are owned by institutional investors?
    94.4M SGMO shares are owned by institutional investors
  • How many SGMO shares are owned by insiders?
    9M SGMO shares are owned by insiders